05/02/14 - 10:58 AM EDT
Citizen Petition filed by Arena's partner Easai is denied by FDA.READ FULL POST
05/02/14 - 09:49 AM EDT
The biotech sector was down again, but there's some hopeful signs of a recovery.READ FULL POST
05/02/14 - 09:01 AM EDT
European regulators are likely to rescind the conditional approval of Endocyte's ovarian cancer drug Vynfinit following the failure of a phase III study.READ FULL POST
04/29/14 - 04:26 PM EDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.READ FULL POST
04/29/14 - 11:24 AM EDT
Two sell-side analysts with very different views Tuesday on Cytokinetics and its experimental ALS drug tirasemtiv.READ FULL POST
04/28/14 - 07:29 AM EDT
Healthcare M&A activity is booming but expensive, risky biotech stocks are left on the sidelines.READ FULL POST
04/15/14 - 12:23 PM EDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.READ FULL POST
04/11/14 - 03:07 PM EDT
Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.READ FULL POST
04/10/14 - 01:09 PM EDT
Wednesday's mini rally was a head fake, leading to more selling Thursday.READ FULL POST
04/10/14 - 11:52 AM EDT
Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.